| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Maosheng Fang, Lehua Li, Jingping Zhao, Honghui Chen, Meng Ye, Xiaofeng Guo, Zheng Lu, Xueli Sun, Chuanyue Wang, Shiping Xie, Bin Hu, Tiansheng Guo, Cui Ma, Bo Wang, Luxian Lü, Na Liu, Hong Deng, Qi Chen, Xiaofang Shang, Fajin Gong, Xiyan Zhang, Xiaolin He, Jianchu Zhou, Yingli Zhan. [Effect of antipsychotic drugs on life quality of schizophrenic patients: one year follow-up study]. Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences. vol 34. issue 9. 2011-05-02. PMID:19779255. |
to compare the effect of 7 antipsychotic drugs on the life quality of schizophrenia patients including chlorpromazine, sulpiride, clozapine, risperidone, olanzapine, quetiapine, and aripiprazole. |
2011-05-02 |
2023-08-12 |
Not clear |
| Hong Liu-Seifert, Bruce J Kinon, Christopher J Tennant, Jennifer Sniadecki, Jan Volavk. Sexual dysfunction in patients with schizophrenia treated with conventional antipsychotics or risperidone. Neuropsychiatric disease and treatment. vol 5. 2011-04-26. PMID:19557099. |
sexual dysfunction in patients with schizophrenia treated with conventional antipsychotics or risperidone. |
2011-04-26 |
2023-08-12 |
Not clear |
| Michael K Raine. Risperidone long-acting injection: a review of its long term safety and efficacy. Neuropsychiatric disease and treatment. vol 4. issue 5. 2011-04-21. PMID:19183782. |
a long-acting form of the second-generation antipsychotic drug risperidone is now broadly available for the treatment of schizophrenia and closely related psychiatric conditions. |
2011-04-21 |
2023-08-12 |
Not clear |
| Ramachandran Naik Soumya, Sandeep Grover, Alakananda Dutt, Navendu Gau. Angioneurotic edema with risperidone: a case report and review of literature. General hospital psychiatry. vol 32. issue 6. 2011-04-04. PMID:21112458. |
a 15-year-old boy diagnosed with schizophrenia was started on risperidone 1 mg/day, which was increased to 2 mg/day after 2 weeks. |
2011-04-04 |
2023-08-12 |
Not clear |
| Todd Lencz, Delbert G Robinson, Barbara Napolitano, Serge Sevy, John M Kane, David Goldman, Anil K Malhotr. DRD2 promoter region variation predicts antipsychotic-induced weight gain in first episode schizophrenia. Pharmacogenetics and genomics. vol 20. issue 9. 2011-03-17. PMID:20664489. |
we therefore examined the relationship between -141c ins/del (rs1799732), a functional promoter region polymorphism in drd2, and antipsychotic-induced weight gain in 58 first episode schizophrenia patients enrolled in a randomized trial of risperidone versus olanzapine. |
2011-03-17 |
2023-08-12 |
Not clear |
| Karisa Cristina Rodrigues Belotto, Nádia Rezende Barbosa Raposo, Aline Siqueira Ferreira, Wagner Farid Gatta. Relative bioavailability of two oral formulations of risperidone 2 mg: A single-dose, randomized-sequence, open-label, two-period crossover comparison in healthy Brazilian volunteers. Clinical therapeutics. vol 32. issue 12. 2011-03-11. PMID:21118746. |
risperidone (rsp) is a benzisoxazole antipsychotic agent used to treat schizophrenia and other psychiatric illnesses in adults and children (including those with autism). |
2011-03-11 |
2023-08-12 |
human |
| Michael Willis, Marianne Svensson, Mickael Löthgren, Bo Eriksson, Anders Berntsson, Ulf Persso. The impact on schizophrenia-related hospital utilization and costs of switching to long-acting risperidone injections in Sweden. The European journal of health economics : HEPAC : health economics in prevention and care. vol 11. issue 6. 2011-03-08. PMID:20084535. |
to estimate changes in resource usage, hospitalization rates, and costs in actual practice in sweden for schizophrenia patients after switching to long-acting injectable risperidone (risperdal consta). |
2011-03-08 |
2023-08-12 |
Not clear |
| Robert A Rosenheck, John H Krystal, Robert Lew, Paul G Barnett, Louis Fiore, Danielle Valley, Soe Soe Thwin, Julia E Vertrees, Matthew H Lian. Long-acting risperidone and oral antipsychotics in unstable schizophrenia. The New England journal of medicine. vol 364. issue 9. 2011-03-08. PMID:21366475. |
long-acting risperidone and oral antipsychotics in unstable schizophrenia. |
2011-03-08 |
2023-08-12 |
Not clear |
| Katja Komossa, Christine Rummel-Kluge, Sandra Schwarz, Franziska Schmid, Heike Hunger, Werner Kissling, Stefan Leuch. Risperidone versus other atypical antipsychotics for schizophrenia. The Cochrane database of systematic reviews. issue 1. 2011-02-28. PMID:21249678. |
risperidone versus other atypical antipsychotics for schizophrenia. |
2011-02-28 |
2023-08-12 |
Not clear |
| S H L Thomas, M D Drici, G C Hall, M A Crocq, B Everitt, M H Lader, C Le Jeunne, D Naber, S Priori, M Sturkenboom, F Thibaut, J Peuskens, A Mittoux, P Tanghøj, M Toumi, N D Moore, R D Man. Safety of sertindole versus risperidone in schizophrenia: principal results of the sertindole cohort prospective study (SCoP). Acta psychiatrica Scandinavica. vol 122. issue 5. 2011-02-25. PMID:20384598. |
safety of sertindole versus risperidone in schizophrenia: principal results of the sertindole cohort prospective study (scop). |
2011-02-25 |
2023-08-12 |
Not clear |
| An Thyssen, Sarah Rusch, Virginie Herben, Jorge Quiroz, Erik Mannaer. Risperidone long-acting injection: pharmacokinetics following administration in deltoid versus gluteal muscle in schizophrenic patients. Journal of clinical pharmacology. vol 50. issue 9. 2011-02-24. PMID:20097933. |
long-acting injectable (lai) risperidone for intramuscular injection into the gluteal muscle every 2 weeks is approved for schizophrenia. |
2011-02-24 |
2023-08-12 |
human |
| Takahiko Nagamin. Serum substance P levels in patients with chronic schizophrenia treated with typical or atypical antipsychotics. Neuropsychiatric disease and treatment. vol 4. issue 1. 2011-02-22. PMID:18728797. |
the present study documented fewer positive episodes of swallowing reflex in patients treated with haloperidol for schizophrenia (7/11; 63.6%) than those treated with risperidone (10/11; 90.9%). |
2011-02-22 |
2023-08-12 |
human |
| Takahiko Nagamin. Serum substance P levels in patients with chronic schizophrenia treated with typical or atypical antipsychotics. Neuropsychiatric disease and treatment. vol 4. issue 1. 2011-02-22. PMID:18728797. |
risperidone, which has little influence on serum substance p productions, may be a more appropriate first-line drug of choice for treatment of schizophrenia. |
2011-02-22 |
2023-08-12 |
human |
| Jeffrey R Bishop, Mani N Pavulur. Review of risperidone for the treatment of pediatric and adolescent bipolar disorder and schizophrenia. Neuropsychiatric disease and treatment. vol 4. issue 1. 2011-02-22. PMID:18728804. |
review of risperidone for the treatment of pediatric and adolescent bipolar disorder and schizophrenia. |
2011-02-22 |
2023-08-12 |
Not clear |
| Jeffrey R Bishop, Mani N Pavulur. Review of risperidone for the treatment of pediatric and adolescent bipolar disorder and schizophrenia. Neuropsychiatric disease and treatment. vol 4. issue 1. 2011-02-22. PMID:18728804. |
risperidone is a commonly used medication for the treatment of bipolar disorder and schizophrenia in children and adolescents. |
2011-02-22 |
2023-08-12 |
Not clear |
| Jeffrey R Bishop, Mani N Pavulur. Review of risperidone for the treatment of pediatric and adolescent bipolar disorder and schizophrenia. Neuropsychiatric disease and treatment. vol 4. issue 1. 2011-02-22. PMID:18728804. |
studies to date indicate that risperidone is an effective treatment for positive and negative symptoms of schizophrenia and mania symptoms of bipolar disorder. |
2011-02-22 |
2023-08-12 |
Not clear |
| Jeffrey R Bishop, Mani N Pavulur. Review of risperidone for the treatment of pediatric and adolescent bipolar disorder and schizophrenia. Neuropsychiatric disease and treatment. vol 4. issue 1. 2011-02-22. PMID:18728804. |
here we review published studies of risperidone for the treatment of bipolar disorder and schizophrenia in children and adolescents to provide practitioners with an overview of published data on the efficacy and safety of risperidone in these patient populations. |
2011-02-22 |
2023-08-12 |
Not clear |
| Ali Ghaleiha, Ahmad Ali Noorbala, Farhad Farnaghi, Mohammad Hajiazim, Shahin Akhondzade. A double-blind, randomized, and placebo-controlled trial of buspirone added to risperidone in patients with chronic schizophrenia. Journal of clinical psychopharmacology. vol 30. issue 6. 2011-02-22. PMID:21105281. |
a double-blind, randomized, and placebo-controlled trial of buspirone added to risperidone in patients with chronic schizophrenia. |
2011-02-22 |
2023-08-12 |
Not clear |
| Ali Ghaleiha, Ahmad Ali Noorbala, Farhad Farnaghi, Mohammad Hajiazim, Shahin Akhondzade. A double-blind, randomized, and placebo-controlled trial of buspirone added to risperidone in patients with chronic schizophrenia. Journal of clinical psychopharmacology. vol 30. issue 6. 2011-02-22. PMID:21105281. |
this study was designed to investigate the effect of buspirone added to risperidone as augmentation therapy in patients with chronic schizophrenia and prominent negative symptoms in a double-blind randomized clinical trial. |
2011-02-22 |
2023-08-12 |
Not clear |
| Sebastian Walther, Helge Horn, Nadja Razavi, Philipp Koschorke, Alexander Wopfner, Thomas J Müller, Werner Stri. Higher motor activity in schizophrenia patients treated with olanzapine versus risperidone. Journal of clinical psychopharmacology. vol 30. issue 2. 2011-02-16. PMID:20520292. |
higher motor activity in schizophrenia patients treated with olanzapine versus risperidone. |
2011-02-16 |
2023-08-12 |
human |